Fewer than 10% of people who could benefit from weight-loss injections like Wegovy are able to get them, states the World Health Organization as it releases its first recommendations on the drugs.
With more than one billion individuals worldwide now obese, it is advocating for increased and just availability to GLP-1 medication.
Based on estimates, in excess of 2,000,000,000 will be living with obesity by 2030 without intervention.
"Our latest guidance affirms that obesity is a long-term condition that can be managed with comprehensive and ongoing support," stated the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and distribution challenges are significant hurdles to broad access to the injections that can help people shift considerable weight, explains the organization.
Skinny Jab Supply Crisis
Despite the present most favorable outlook, the production of these medications might only reach about 100 million people – fewer than 10% of eligible patients, according to the health organization.
The recommendation calls on nations and manufacturers to widen access, through measures such as voluntary licensing.
The intellectual property rights on a key compound – the main ingredient of the drug Wegovy – is scheduled to end in a number of nations in 2026.
How Weight-Loss Jabs Work
The injections imitate a biological compound to reduce digestion speed, curb appetite and enhance feelings of fullness so individuals reduce food intake.
Individuals commonly begin shedding pounds in the initial weeks of beginning the weekly injections.
Studies points to people may put most of the weight back on a year later of halting the drug, as their usual food cravings resume.
Being above a healthy weight elevates your chance for developing medical conditions, such as type 2 diabetes, cardiovascular issues, brain attack, and specific malignancies.
Excess weight affects people in every country and was linked to 3.7 million deaths worldwide in 2024, as per the WHO.
